Back
75· Active
Health & Science1h 34m ago
An independent panel of experts voted unanimously that the benefits of Eli Lilly’s experimental Alzheimer’s drug, donanemab, outweigh the risks.
Silver Spring, Maryland, USA
Who
U.S. Food and Drug Administration (FDA) Panel
What
An independent panel of experts voted unanimously that the benefits of Eli Lilly’s experimental Alzheimer’s drug, donanemab, outweigh the risks.
When
Wed, 10 Jun 2026 10:40:06 GMT · 1h 34m ago
Where
Silver Spring, Maryland, USA · 39.0331°N, 76.9904°W
Why
Clinical data showed the drug significantly slowed cognitive and functional decline in patients with early-stage Alzheimer's by clearing amyloid plaques.
The Frontline Impact
How this affects you
The positive endorsement paves the way for a final FDA approval decision later this year, potentially offering a new treatment option for millions of Alzheimer’s patients.
Story chain
1 event in this threadNo related history yet — this is the origin event.
Verified Sources & Citations
Credibility ratings reflect the AI ingestion pipeline's assessment of source provenance.